Top

Published in:

01-06-2012 | Thoracic Oncology

Cytokeratin 7 is a Predictive Marker for Survival in Patients with Esophageal Squamous Cell Carcinoma

Authors: Naohide Oue, MD, PhD, Tsuyoshi Noguchi, MD, PhD, Katsuhiro Anami, MD, PhD, Seigo Kitano, MD, PhD, Naoya Sakamoto, MD, PhD, Kazuhiro Sentani, MD, PhD, Naohiro Uraoka, MD, Kazuhiko Aoyagi, PhD, Teruhiko Yoshida, MD, Hiroki Sasaki, PhD, Wataru Yasui, MD, PhD

Published in: Annals of Surgical Oncology | Issue 6/2012

Abstract

Background

Patients diagnosed with stage II and III esophageal squamous cell carcinoma (ESCC) have variable prognosis. This group would benefit greatly from the discovery of prognostic markers that are capable of identifying individuals for whom adjuvant treatment would be advantageous. The aim of this study was to investigate the impact of immunohistochemically detected cytokeratin 7 (CK7) expression on disease-free survival, overall survival (OS), or therapeutic outcome in patients with ESCC.

Methods

Immunohistochemical analysis of CK7 was performed on 225 surgically resected specimens of stage 0–III ESCC.

Results

In total, 20 (9%) of 225 ESCC cases were positive for CK7. In stage 0–III ESCC patients, CK7 expression was statistically significantly associated with OS, independent of clinical covariates, including tumor, node, metastasis system stage. In stage II and III ESCC patients (n = 124), CK7 expression was significantly associated with poorer OS (P = 0.0377). Furthermore, in stage II and III ESCC patients who did not receive adjuvant chemotherapy (n = 73), CK7 expression was significantly associated with poorer OS (P = 0.0003). CK7 expression was not associated with therapeutic outcome in patients with stage II and III ESCC who received adjuvant chemotherapy. In patients with CK7-positive ESCC (n = 16), receipt of adjuvant chemotherapy tended to be beneficial for patients with stage II and III ESCC (P = 0.0654).

Conclusions

Immunohistochemical analysis of CK7 will help to identify high-risk patients.

Available only for authorised users

IARC 2003 Oesophageal cancer. In: Stewart BW, Kleihues P (eds) World cancer report. Lyon: IARC Press, pp. 223–7.

Goseki N, Koike M, Yoshida M. Histopathologic characteristics of early stage esophageal carcinoma. A comparative study with gastric carcinoma. Cancer. 1992;69:1088–93.PubMedCrossRef

Courrech Staal EF, van Coevorden F, Cats A, Aleman BM, van Velthuysen ML, Boot H et al. Outcome of low-volume surgery for esophageal cancer in a high-volume referral center. Ann Surg Oncol. 2009;16:3219–26.PubMedCrossRef

Takeno S, Noguchi T, Kikuchi R, Uchida Y, Yokoyama S, Müller W. Prognostic value of cyclin B1 in patients with esophageal squamous cell carcinoma. Cancer. 2002;94:2874–81.PubMedCrossRef

Noguchi T, Oue N, Wada S, Sentani K, Sakamoto N, Kikuchi A et al. h-Prune is an independent prognostic marker for survival in esophageal squamous cell carcinoma. Ann Surg Oncol. 2009;16:1390–6.PubMedCrossRef

Isohata N, Aoyagi K, Mabuchi T, Daiko H, Fukaya M, Ohta H et al. Hedgehog and epithelial-mesenchymal transition signaling in normal and malignant epithelial cells of the esophagus. Int J Cancer. 2009;125:1212–21.PubMedCrossRef

Sakamoto N, Oue N, Noguchi T, Sentani, K., Anami, K., Sanada, Y, et al. Serial analysis of gene expression of esophageal squamous cell carcinoma: ADAMTS16 is upregulated in esophageal squamous cell carcinoma. Cancer Sci. 2010;101:1038–44.PubMedCrossRef

Sano M, Aoyagi K, Takahashi H, Kawamura T, Mabuchi T, Igaki H, et al. Forkhead box A1 transcriptional pathway in KRT7-expressing esophageal squamous cell carcinomas with extensive lymph node metastasis. Int J Oncol. 2010;36:321–30.PubMed

Moll R, Divo M, Langbein L. The human keratins: biology and pathology. Histochem Cell Biol. 2008;129:705–33.PubMedCrossRef

10.

Yamada A, Sasaki H, Aoyagi K, Sano M, Fujii S, Daiko H, et al. Expression of cytokeratin 7 predicts survival in stage I/IIA/IIB squamous cell carcinoma of the esophagus. Oncol Rep. 2008;20:1021–7.PubMed

11.

Sobin LH, Wittekind CH, editors. TNM classification of malignant tumors. 6th ed. New York: Wiley-Liss, 2002:60–4.

12.

Haleem A, Kfoury H, Al Juboury M, Al Husseini H. Paget’s disease of the oesophagus associated with mucous gland carcinoma of the lower oesophagus. Histopathology. 2003;42:61–5.PubMedCrossRef

Title: Cytokeratin 7 is a Predictive Marker for Survival in Patients with Esophageal Squamous Cell Carcinoma
Authors: Naohide Oue, MD, PhD
Tsuyoshi Noguchi, MD, PhD
Katsuhiro Anami, MD, PhD
Seigo Kitano, MD, PhD
Naoya Sakamoto, MD, PhD
Kazuhiro Sentani, MD, PhD
Naohiro Uraoka, MD
Kazuhiko Aoyagi, PhD
Teruhiko Yoshida, MD
Hiroki Sasaki, PhD
Wataru Yasui, MD, PhD
Publication date: 01-06-2012
Publisher: Springer-Verlag
Published in: Annals of Surgical Oncology / Issue 6/2012
Print ISSN: 1068-9265
Electronic ISSN: 1534-4681
DOI: https://doi.org/10.1245/s10434-011-2175-4

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Cytokeratin 7 is a Predictive Marker for Survival in Patients with Esophageal Squamous Cell Carcinoma

Abstract

Background

Methods

Results

Conclusions

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2012

Hereditary Breast and Ovarian Cancer and Other Hereditary Syndromes: Using Technology to Identify Carriers

Prognostic Value of Preoperative Metabolic Tumor Volume and Total Lesion Glycolysis in Patients with Epithelial Ovarian Cancer

SIRT1 Promotes Tumorigenesis and Resistance to Chemotherapy in Hepatocellular Carcinoma and its Expression Predicts Poor Prognosis

Has the Survival Rate for Surgically Resected Gastric Gastrointestinal Stromal Tumors Improved in the Tyrosine Kinase Inhibitor Era?

Sentinel Lymph Node Procedure Leads to Upstaging of Patients with Resectable Colon Cancer: Results of the Swiss Prospective, Multicenter Study Sentinel Lymph Node Procedure in Colon Cancer

Prognostic Value of Number of Removed Lymph Nodes, Number of Involved Lymph Nodes, and Lymph Node Ratio in 7502 Breast Cancer Patients Enrolled onto Trials of the Austrian Breast and Colorectal Cancer Study Group (ABCSG)